North America Heart Pump Device Market Set to Reach $8.1 Billion by 2033

According to Renub Research Latest Report North America Heart Pump Device Market is witnessing robust growth, projected to expand from US$ 2.92 billion in 2024 to US$ 8.1 billion by 2033, representing a Compound Annual Growth Rate (CAGR) of 12% from 2025 to 2033. This surge is fueled by a combination of increasing cardiovascular disease incidence, technological advancements in heart pump devices, and the region's growing geriatric population. The adoption of life-supporting and minimally invasive cardiac devices is rapidly rising across hospitals and specialized cardiac centers in both the United States and Canada.

Understanding Heart Pump Devices

A heart pump device is a mechanical system designed to aid or augment heart function in patients with severe cardiovascular conditions, particularly heart failure. Devices such as left ventricular assist devices (LVADs) and total artificial hearts (TAHs) are primarily used to enhance blood flow and sustain life for patients awaiting transplants or those who are not candidates for surgery.

Heart pump devices help relieve symptoms associated with heart failure, including:

Fatigue

Shortness of breath

Fluid retention

By improving circulation, these devices enable patients to maintain a better quality of life. They are also crucial in critical care situations, such as during high-risk cardiac surgeries or recovery after heart attacks.

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Sample Report

Key Growth Drivers

1. Rising Prevalence of Cardiovascular Diseases

The North America heart pump device market is strongly influenced by the growing incidence of cardiovascular diseases such as heart failure, coronary artery disease, and arrhythmias. According to recent statistics, 919,032 individuals in the U.S. succumbed to cardiovascular disease in 2023, accounting for roughly 1 in every 3 deaths.

Key contributing factors include:

Aging population: The proportion of seniors (65+) in Canada is projected to grow from 18.5% in 2021 to between 21.6% and 29.8% by 2068. Aging increases susceptibility to heart failure.

Lifestyle-related diseases: Obesity, diabetes, and hypertension contribute significantly to cardiovascular risk.

This growing patient base drives demand for life-supporting devices like ventricular assist devices (VADs) and intra-aortic balloon pumps (IABPs).

2. Technological Innovations in Heart Pump Devices

The rapid pace of technological advancement is another major driver. Manufacturers are focusing on:

Miniaturization of devices for less invasive procedures

Biocompatible materials to reduce thrombosis and infection

Wireless energy transfer and remote monitoring

Extended battery life for implanted devices

Recent developments have expanded treatment options. For instance, Johnson & Johnson MedTech reported FDA approval of the Impella 5.5 with SmartAssist and Impella CP with SmartAssist for certain pediatric patients with acute heart failure. These innovations reduce recovery time, improve outcomes, and broaden the range of patients who can benefit from mechanical circulatory support.

3. Supportive Reimbursement and Healthcare Infrastructure

North America’s robust healthcare systems significantly support market growth. Key factors include:

Medicare, Medicaid, and private insurers in the U.S. cover a wide range of cardiac interventions.

Canada’s single-payer system ensures access to advanced devices such as VADs and IABPs.

Availability of specialized cardiac centers and trained surgeons increases adoption.

Ongoing professional education and clinical training improve surgical success rates.

These factors collectively make advanced heart pump devices more accessible and clinically viable in the region.

Challenges Facing the Market

1. High Costs

Despite reimbursement support, the exorbitant cost of devices and implantation procedures limits adoption:

Ventricular assist devices can cost tens of thousands of dollars, excluding hospitalization and follow-up care.

Hospitals bear the financial burden of procurement and maintenance, which can delay device implementation.

High out-of-pocket expenses remain a barrier for low-income patients, slowing market penetration in certain segments.

2. Device-Related Risks

Heart pump devices, while life-saving, carry inherent risks, including:

Blood clots and stroke

Bleeding and infection

Mechanical malfunction requiring replacement surgery

Long-term monitoring and strict adherence to medical regimens can be challenging, especially for older patients. Consequently, doctors may reserve devices for severe cases, limiting broader adoption in moderate heart failure patients.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Market Segmentation and Outlook

By Product

Ventricular Assist Devices (VADs) – increasingly used for end-stage heart failure, bridging patients to transplant, or as destination therapy. Miniaturization and durability improvements drive adoption.

Intra-Aortic Balloon Pumps (IABPs) – less invasive, widely used in acute myocardial infarction or cardiogenic shock for emergency stabilization.

Extracorporeal Membrane Oxygenation (EMCO) – supports patients in critical cardiac and respiratory failure.

Total Artificial Hearts (TAHs) – offer complete replacement in severe cases, though adoption is limited due to cost and complexity.

By Type

Implanted Devices – long-term circulatory support, improving survival and quality of life for transplant-ineligible patients.

Extracorporeal Devices – used short-term in critical care or perioperative scenarios.

By End Use

Hospitals – primary adoption centers due to surgical facilities and intensive care support.

Cardiac Centers – specialized intervention hubs offering high-end treatments and clinical trials.

Research Institutes – limited adoption for experimental and trial purposes.

Regional Insights

United States

The U.S. dominates the North American market:

High healthcare expenditure and sophisticated infrastructure facilitate adoption.

Positive reimbursement policies allow wider patient access to VADs, IABPs, and implantable devices.

Leading medical device companies and research centers are located here, accelerating innovation and clinical adoption.

Recent clinical trials highlight ongoing progress. For example, University of Michigan surgeons implanted a novel mechanical heart pump as part of a study comparing it to existing therapy for end-stage heart failure.

Canada

Canada’s unified healthcare system ensures equitable access:

Aging population and rising risk factors like diabetes and obesity drive demand.

Adoption is slower compared to the U.S. due to regulation and funding mechanisms, but access equity remains strong.

Advanced cardiac facilities increasingly implement implanted devices such as HeartMate 3™ LVAD.

Hospital and Cardiac Center Market Dynamics

Hospitals

Key adoption hubs due to operating rooms, ICUs, and specialized personnel.

Major share of heart pump device utilization comes from hospitals performing complex procedures.

U.S. tertiary care facilities lead in device adoption, with Canadian hospitals contributing significantly via public funding.

Cardiac Centers

Specialized facilities focus solely on advanced cardiovascular interventions.

Enable personalized treatment, reduced recovery time, and access to investigational devices.

U.S. leads with private and academic centers, while Canada is expanding specialized cardiac care facilities.

Key Players in North America

Prominent companies driving market growth include:

Abbott Inc. – innovator in LVAD technology

Getinge AB – provider of circulatory support solutions

Teleflex Incorporated – known for intra-aortic balloon pumps

Fresenius SE & Co. KGaA – expanding mechanical support offerings

LivaNova PLC – specializing in cardiac devices

CorWave SA, JARVIK HEART, INC., ABIOMED – pioneers in innovative heart pump technology

These companies focus on R&D, clinical trials, and strategic partnerships to expand market presence and enhance product offerings.

Future Outlook

The North America Heart Pump Device Market is poised for continued growth through 2033:

Technological advancements, including smaller, fully implantable, and remotely monitored devices, will drive adoption.

Increasing cardiovascular disease prevalence and an aging population will sustain demand.

Supportive healthcare infrastructure and reimbursement policies will continue to enable patient access.

Despite challenges such as high costs and device-related risks, ongoing innovations and clinical trials indicate a positive trajectory, particularly for ventricular assist devices and implantable solutions. Hospitals and cardiac centers will remain central to market expansion, ensuring patients with advanced heart failure receive life-sustaining interventions.

Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.